Definium Therapeutics says DT120 met Phase 3 GAD endpoints
The company says its Phase 3 Panorama study for DT120 ODT 100 µg met all primary and key secondary endpoints for reducing anxiety symptoms in GAD, with rapid, sustained efficacy and a favorable safety profile. The company plans an NDA submission for 2027.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.